Label-free impedance-based assays are increasingly used to non-invasively study ligand-induced GPCR activation in cell culture experiments. The approach provides real-time cell monitoring with a device-dependent time resolution down to several tens of milliseconds and it is highly automated. However, when sample numbers get high (e.g., dose-response studies for various different ligands), the cost for the disposable electrode arrays as well as the available time resolution for sequential well-by-well recordings may become limiting. Therefore, we here present a serial agonist addition protocol which has the potential to significantly increase the output of label-free GPCR assays. Using the serial agonist addition protocol, a GPCR agonist is added sequentially in increasing concentrations to a single cell layer while continuously monitoring the sample's impedance (agonist mode). With this serial approach, it is now possible to establish a full dose-response curve for a GPCR agonist from just one single cell layer. The serial agonist addition protocol is applicable to different GPCR coupling types, Gq Gi/0 or Gs and it is compatible with recombinant and endogenous expression levels of the receptor under study. Receptor blocking by GPCR antagonists is assessable as well (antagonist mode).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3791/60686 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Alzheimers Res Ther
January 2025
Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile. Semaglutide may have a disease-modifying, neuroprotective effect in AD through multimodal mechanisms including neuroinflammatory, vascular, and other AD-related processes.
View Article and Find Full Text PDFA phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies.
Clin Cancer Res
January 2025
Stanford University, Stanford, CA, United States.
Purpose: Activating T cell costimulatory receptors is a promising approach for cancer immunotherapy. In preclinical work, adding an OX40 agonist to in situ vaccination (ISV) with SD101, a TLR9 agonist, was curative in a mouse model of lymphoma. We sought to test this combination in a Phase I clinical trial for patients with low-grade B cell lymphoma.
View Article and Find Full Text PDFSafety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal Activation.
Drug Des Devel Ther
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Background: HY209 is a synthesized sodium taurodeoxycholate (TDCA) that is expected to serve as a novel treatment for sepsis by inhibiting the inflammasomal activation that suppresses the production of pro-inflammatory cytokines. This study aimed to assess the safety, tolerability and pharmacokinetics (PKs) of HY209 after intravenous administration in healthy subjects.
Methods: A dose-block randomized, double-blind, placebo-controlled, single ascending dose study was conducted.
Breathing Easy During Training. Strategies for Managing Exercise-Induced Bronchoconstriction.
Immunol Allergy Clin North Am
February 2025
National Institute of Respiratory Diseases, Mexico City, Mexico. Electronic address:
Article Synopsis
- * Short-acting beta-agonists are the main treatment recommended for managing symptoms, and it's essential for patients, especially children, to avoid triggers that can worsen their condition.
- * Physicians should regularly evaluate treatment effectiveness, but athletes may need specialized testing to create personalized management plans that balance health and performance.
Therapies Used by Children With Primary Ciliary Dyskinesia: A Natural History Study.
Pediatr Pulmonol
November 2024
Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Article Synopsis
- - A study evaluated the management of primary ciliary dyskinesia (PCD) in pediatric participants using a multicenter, observational approach, collecting data on therapy types and their annual usage.
- - Over 137 participants were monitored for 13 years, finding that nearly all received antibiotics, with a significant number using cephalosporins and chronic azithromycin, and older patients tended to utilize more therapies.
- - Results indicated that therapy usage varies significantly, often correlating with age and specific types of ciliary defects, highlighting the need for more disease-specific research to better understand the effectiveness of these treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!